Innate Pharma Files 6-K Report with Press Release
Ticker: IPHYF · Form: 6-K · Filed: Apr 29, 2025 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Apr 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, press-release, foreign-private-issuer
TL;DR
Innate Pharma dropped a 6-K with a press release on 4/29/25 - check it for news.
AI Summary
On April 29, 2025, Innate Pharma SA filed a Form 6-K report. This filing includes a press release dated April 29, 2025, as Exhibit 99.1. The company is a foreign private issuer and files its annual reports under Form 20-F.
Why It Matters
This filing provides an update from Innate Pharma SA, potentially containing material information for investors regarding the company's operations or strategic developments.
Risk Assessment
Risk Level: low — This filing is a routine report of a foreign private issuer and does not appear to contain significant new financial or operational disclosures.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- April 29, 2025 (date) — Filing and Press Release Date
- 001-39084 (other) — Commission File Number
- Form 20-F (other) — Annual Report Form
- Exhibit 99.1 (other) — Press Release
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report information that Innate Pharma SA is required to disclose to its security holders or the public under French law, including the attached press release dated April 29, 2025.
What is the Commission File Number for Innate Pharma SA?
The Commission File Number for Innate Pharma SA is 001-39084.
Does Innate Pharma SA file its annual reports under Form 20-F or Form 40-F?
Innate Pharma SA files its annual reports under cover of Form 20-F.
What is included as an exhibit in this filing?
Exhibit 99.1, a Press Release dated April 29, 2025, is included in this filing.
Where is Innate Pharma SA's principal executive office located?
Innate Pharma SA's principal executive office is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 29, 2025 regarding Innate Pharma SA (IPHYF).